2026 Q3 Portfolio Activity
In 2026 Q3, Royalty Pharma Sub-Manager, LLC maintained a portfolio of 5 distinct positions. The most significant new addition was ZENAS BIOPHARMA, INC., now representing 32.82% of the total fund value. Conversely, Royalty Pharma Sub-Manager, LLC completely exited their position in ZENAS BIOPHARMA, INC..
Position History
hover any row below to update
Loading…
Total Positions
5
Quarter
2026 Q3
Top Holding
CYTK (32.9%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-5 of 5
Royalty Pharma Sub-Manager, LLC Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CYTK
CYTOKINETICS, I...
|
Healthcare | 32.92% | 34.52% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
980,392 | $64,617,637 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ZBIO
ZENAS BIOPHARMA...
|
Healthcare | 32.82% | — |
#2
Prev: #—
|
9.0 |
—
|
2,388,150 | — |
NEW
|
2,388,150 | $64,408,406 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 19.97% | 18.06% |
#3
1
Prev: #4
|
6.0 |
—
|
no change | no change |
P
S
|
2,936,507 | $39,202,368 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
KLRA
KAILERA THERAPE...
|
Healthcare | 14.29% | 22.36% |
#4
1
Prev: #3
|
5.5 |
—
|
no change | no change |
P
S
|
2,455,357 | $28,040,177 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
BCAX
ZENAS BIOPHARMA...
|
Healthcare | 0.00% | 25.05% |
Sold All 😨
(Was: #2) |
0.0 |
—
|
-2,388,150 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 |
Showing 1-5 of 5 holdings